Dr. Sagar Lonial on Understanding Multiple Myeloma

Addressing Current Questions and Controversies in the Management of Multiple MyelomaПодробнее

Data + Perspectives: Multiple Myeloma (5 of 5)Подробнее

The Significance of the MMRF featuring Sagar Lonial, MDПодробнее

Selecting and sequencing therapies in newly diagnosed myelomaПодробнее

2022 Research Round Up: Multiple Myeloma, Breast Cancer, and Cancer in Adults 60 and OverПодробнее

Using MRD Adapted Strategy (MIDAS) to guide myeloma treatment | Sagar Lonial, MD, FACP | IMS 2024Подробнее

Selecting and sequencing therapies for R/R multiple myelomaПодробнее

A trial investigating IberVd in transplant-ineligible newly diagnosed multiple myelomaПодробнее

Iberdomide – efficacy and safety in RRMMПодробнее

A Roadmap to Safe and Effective Bispecific Antibody Use in Myeloma: Mitigating and Managing Adver...Подробнее

Treatment Sequencing Considerations for Using CAR-T in Patients with Multiple MyelomaПодробнее

Where Does CAR-T Fit in the Myeloma Treatment Algorithm?Подробнее

Myeloma Panel Compares Real-World Versus Clinical Trial Data for CAR-Ts, BispecificsПодробнее

Final analysis of the DREAMM-2 trial: belantamab mafodotin for R/R multiple myelomaПодробнее

Myeloma Crowd Radio: Sagar Lonial, MD, Winship Cancer InstituteПодробнее

What Is the Future for CAR-T in Multiple Myeloma?Подробнее

"We Are Seeing SO Much Progress in This Blood CANCER!"Подробнее

Myeloma Treatment Selection: CAR-T Versus Bispecific T-Cell Engagers, Bridging Therapy OptionsПодробнее

IMS Highlights for Triple Class Refractory Myeloma | Sagar Lonial, MD, FACP | IMS 2023Подробнее

Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma | Meet The Professors Live: Clinical ...Подробнее